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529Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and
Mortality in Hemodialysis PatientsObjectives TSeehis study sought to assess whether spironolactone treatment reduces the high incidence of cardiovascular and
cerebrovascular (CCV) morbidity and mortality in hemodialysis (HD) patients.Background Aldosterone receptor blockers reduce cardiac-related events, but the efﬁcacy of the agents in HD patients is unclear.Methods A 3-year randomized trial involving 5 clinics was performed. Of the 309 oligoanuric HD patients enrolled in the study,
157 patients were randomly assigned to receive 25 mg/day of spironolactone without any restriction on dietary
potassium intake (treatment group), and 152 patients were assigned to a control group. The primary outcome was
a composite of death from CCV events or hospitalization for CCV events, and the secondary outcome was death from all
causes.Results During the 3-year follow-up, the primary outcome occurred in 5.7% of patients in the treatment group and in
12.5% of patients in the control group. Hazard ratios (HRs) for the primary outcome for treatment were 0.404
(95% conﬁdence interval [CI]: 0.202 to 0.809; p ¼ 0.017) and 0.379 (95% CI: 0.173 to 0.832; p ¼ 0.016) before
and after adjustment, respectively. The secondary outcome was signiﬁcantly reduced in the treatment group
compared with the control group (6.4% vs. 19.7%; HRs: 0.355 [95% CI: 0.191 to 0.662; p ¼ 0.002] and 0.335
[95% CI: 0.162 to 0.693; p ¼ 0.003] before and after adjustment, respectively). Gynecomastia or breast pain was
reported in 16 patients (10.2%) in the treatment group. Serious hyperkalemia led to treatment discontinuation in
3 patients (1.9%).Conclusions Aldosterone receptor blockade using spironolactone may substantially reduce the risk of both CCV morbidity
and death among HD patients; however, larger-scale studies are recommended to further conﬁrm its efﬁcacy.
(Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients;
NCT01687699) (J Am Coll Cardiol 2014;63:528–36) ª 2014 by the American College of Cardiology FoundationPatients with end-stage renal disease (ESRD) undergoing
dialysis are at a particularly high risk of cardiovascular and
cerebrovascular (CCV) disease, accounting for 40% to 50%
of deaths (1,2). Medical therapy involving the use of agents
for the renin-angiotensin-aldosterone system (RAAS) is
expected to have a signiﬁcant impact, because the results of
large-scale trials have shown that angiotensin-converting
enzyme inhibitors (ACEIs) or angiotensin receptor blockers
(ARBs) are beneﬁcial for CCV events in the general pop-
ulation (3–5). However, data supporting the positive effects of
these agents in ESRD patients on dialysis are limited (6). For
this, it is necessary to evaluate the RAAS components that
need to be blocked, so that favorable outcomes can be
obtained in patients with different disease severity levels or
complications.page 537Recent studies suggest that the protection mechanism of
these blockers could be attributed to a change in either the
qualitative or quantitative pathological functions of aldoste-
rone rather than that of angiotensin II (7). In fact, a series
beginning with RALES (Randomized Aldactone Evaluation
Study) has shown a strong association of aldosterone with
a risk of cardiovascular events, including sudden cardiac death
(SCD) (8–10). The interactions between cardiovascular disease
and cerebrovascular disease have been widely developed over thepast 2 decades, and aldosterone blockade has shown protective
effects on ischemic cerebral infarct size and cerebrovascular
remodeling in stroke-prone rats (11,12). Therefore, clinicians
have attempted to improve the outcomes of dialysis patients by
managing CCV disease using aldosterone blockade, including
spironolactone. However, lack of detailed information on the
adverse-effects proﬁle of spironolactone for dialysis patients
limits its use.The major concern with administrating spi-
ronolactone to patients with renal failure is life-threatening
hyperkalemia. Nevertheless, oligoanuric patients requiring
dialysis may not be at a risk of spironolactone-induced hyper-
kalemia when extrarenal potassium disposable (e.g., colonic
transport) is marginal. Our pilot study (13) and several previous
small studies (14,15) have suggested that spironolactone can be
safely administered to patients under hemodialysis (HD)
without the development of serious hyperkalemia.
On the basis of these data, we designed DOHAS
(Dialysis Outcomes Heart Failure Aldactone Study) to test
the hypothesis that daily treatment with low-dose spi-
ronolactone would signiﬁcantly reduce the risk of death from
all causes and CCV morbidity in patients with ESRD
undergoing HD.Methods
Patients. Eligibility criteria were determined by reviewing
the medical records and laboratory data of patients. HD
patients who were at least 30 years of age, had undergone
Abbreviations
and Acronyms
ACEI = angiotensin-
converting enzyme inhibitor
ARB = angiotensin receptor
blocker
CCV = cardiovascular and
cerebrovascular
CI = conﬁdence interval
CT = computed tomography
CTR = cardiothoracic ratio
ESRD = end-stage renal
disease
HD = hemodialysis
HR = hazard ratio
MRI = magnetic resonance
imaging
RAAS = renin-angiotensin-
aldosterone system
SCD = sudden cardiac death
TIA = transient ischemic
attack
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5304-h-long HD 3 times a week for
at least 2 years, and had an
average serum potassium level
(immediately before dialysis on
the ﬁrst day of the week) of
<6.5 mEq/l over the previous 2
months and a 24-h urinary output
of <500 ml were included in the
study. The exclusion criteria in-
cluded a history of noncompliance
(including noncompliance with
HD), unstable vascular access,
hypotension, hepatic failure, active
malignancy, or any life-
threatening disease other than
ESRD. Patients were recruited
from 5 Japanese outpatient HD
clinics afﬁliated with a teaching
hospital. Recruitment began in
April 2008 and was completed in
December 2008. Finally, 309
patients were registered in the
study. Patients were able to receive
standard medications such asvitamin D, phosphate binders, erythropoietin, and antihyper-
tensive agents (including ACEIs, ARBs, and beta-blockers).
Study design and procedure. DOHAS was a prospective,
multicenter, randomized, controlled, open-label trial. After
registration, patients were randomly assigned to either the
spironolactone treatment group or the control group. The
treatment group was administered an oral spironolactone
dose of 25 mg/day as a 3-year plan. Study medication was
withheld in the event of life-threatening hyperkalemia
(serum potassium level >6.8 mEq/l), gynecomastia, breast
pain, or any condition wherein discontinuation of spi-
ronolactone treatment was deemed medically necessary by
the physician responsible for the patient. Patients who
moved to other dialysis facilities outside of the 5 clinics
included in the study or who were found to have a malig-
nancy were discontinued from the study. Pre-enrollment
medication that may have affected serum potassium levels
(e.g., ACEIs, ARBs, loop diuretics, and ion exchange resins)
were not changed during the study. HD prescriptions,
including dialyzer type, dialysate composition, blood ﬂow
rate, and dialysate ﬂow rate, were not changed. Dialysate
potassium concentration was 2.0 mEq/l for all patients.
No additional dietary potassium restrictions beyond the usual
recommendations were imposed. Routine laboratory assess-
ments, including serum potassium levels, were repeated twice
a month for all patients. Adverse events other than hyper-
kalemia were also assessed during the treatment period.
The trial complied with the principles of the Declaration
of Helsinki and was approved by the ethics committee at
each study clinic. All patients provided written informed
consent. An independent data and safety monitoring board
periodically reviewed the results in a blinded fashion. Eventcommittees whose members were unaware of treatment
assignments assessed the causes of death and reasons for
hospitalization. There was no commercial support or
involvement in this trial.
Study outcomes. The primary outcome of the study was
a composite of death from CCV events or hospitalization for
CCV events. CCV events included new occurrence or
exacerbation of heart failure that was not improved by water
removal through dialysis (clinical symptoms together with
left ventricular dysfunction by echocardiography according
to the American Heart Association [AHA]/American
College of Cardiology [ACC] guidelines), malignant
ventricular arrhythmias (ventricular ﬁbrillation or sustained
ventricular tachycardia), new or recurrent acute myocardial
infarction (changes on electrocardiography [ECG] and
biomarkers for myocardial infarction), new occurrence or
exacerbation of angina pectoris (ECG change corresponding
to chest symptoms and coronary angiography showing
>75% stenosis according to AHA/ACC guidelines), dis-
secting aneurysm of the aorta (diagnosed by imaging tech-
niques), stroke (diagnosed by computed tomography [CT]
and/or magnetic resonance imaging [MRI]), new or recur-
rent transient ischemic attack (TIA) (diagnosed by CT and/
or MRI, and sudden onset of neurological deﬁcit persisting
for <24 h), and SCD. According to the Hemodialysis
Study, SCD was deﬁned as an unexpected death, with
a preceding symptom duration of <24 h for witnessed
deaths and less than the interval since the last dialysis session
for unwitnessed deaths (16). The secondary outcome was
death from any cause. The causes of death were classiﬁed
into cardiovascular events (CCV events other than stroke
and TIA), cerebrovascular events (stroke and TIA), and
others.
Sample size. Few epidemiological data about CCV risk in
Japan were available; hence, the sample size was determined
such that the study will be adequately powered for the
analysis of the secondary endpoint, time from randomization
to death. On the basis of the results of a previous report (17),
mortality in the control group was anticipated to be 10% per
year. Our original calculation suggested that a sample size of
600 patients was appropriate to detect a hazard-ratio
reduction of 40% in the mortality of the treatment group
compared with that of the control group at a 2-sided alpha
level of 0.05, with 80% power. The study commenced in
April 2008; however, because of slow recruitment owing to
participation refusal, recruitment closed in December 2008.
Statistical analysis. Baseline characteristics were compared
between the 2 groups. A Fisher’s exact test or chi-square test
was used for categorical data, and a Student t test was used
for quantitative data. A p value of <0.05 was considered
statistically signiﬁcant.
The analyses of primary and secondary outcomes were
conducted by an independent statistician on the basis of the
intention-to-treat principle. For multiple CCV events
observed in a single patient, only the ﬁrst CCV event was
analyzed as a primary outcome. First, univariate analyses
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531were constructed to determine the difference between the
treatment and control group in the primary outcome and its
components (cardiovascular events, cerebrovascular events,
and sudden death) and in the secondary outcome and its
components (death from CCV events, cardiovascular death,
and cerebrovascular death). Kaplan-Meier curves were drawn
to visualize the primary and secondary outcome distribution
over time for the treatment and control groups, and a
comparison between the 2 groups was made on the basis of a
Cox-Mantel test. Second, a multivariate analysis using a Cox
proportional hazards regression model was constructed to
determine the difference between the 2 groups in the primary
and secondary outcomes with adjustment for sex, duration of
dialysis, and cardiothoracic ratio (CTR) to explore the effects
of baseline variables. Hazard ratios (HRs), 95% conﬁdence
intervals (CIs), and p values were calculated. Lastly, the
consistency of the treatment effect on the 2 main outcomes
was assessed among 8 pre-deﬁned subgroups, namely, age,
sex, duration of dialysis, systolic and diastolic blood pressure,
the use of ACEIs or ARBs, CTR, and serum albumin
concentration. The effect in each subgroup was analyzed with
the use of an unadjusted Cox model, and p values for theTable 1 Baseline Characteristics of the Study P
Variable
Spironolactone 25 mg/da
(n ¼ 157)
Age, yrs 67.4  12.3
Sex
Female 44 (28.0)
Male 113 (72.0)
Duration of dialysis, months 99.9  82.2
Principal cause of ESRD
Diabetes 50 (31.8)
Hypertension 20 (12.7)
Glomerulonephritis 61 (38.9)
Polycystic kidney disease 8 (5.1)
Other 18 (11.5)
Blood pressure, mm Hg
Systolic 152.1  22.5
Diastolic 77.4  13.6
Medical history
Atrial ﬁbrillation 13 (8.3)
PCI 22 (14.0)
Cardiac surgery or aorta surgery 5 (3.2)
Medication
ACEI 14 (8.9)
ARB 64 (40.8)
ACEI, ARB, or both 67 (42.7)
Beta-blocker 14 (8.9)
Ion exchange resin 24 (15.3)
Cardiothoracic ratio, % 49.5  4.9
Urea reduction ratio, % 69.6  4.7
Hemoglobin, g/dl 10.3  1.0
Serum albumin, g/dl 3.84  0.26
Serum creatinine, mg/dl 11.3  2.4
Values are mean  SD or n (%).
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin rec
coronary intervention.interaction were calculated using a Cox proportional hazards
regression model with adjustment for the subgroup item. All
analyses of outcomes were conducted using DANS version
7.1 (Sugimoto Data Analysis Service, Nagoya, Japan).Results
Study patients. Some signiﬁcant differences in baseline
characteristics between the treatment group (n ¼ 157) and
the control group (n ¼ 152) were observed (Table 1), with
average dialysis duration 27 months longer, serum albumin
level 0.08 g/dl lower, and CTR 1.5% greater in the control
group than in the treatment group.
There were 45 patients in the treatment group and 24
in the control group who were discontinued from the
study. There were 28 patients (12 in the treatment group
and 16 in the control group) who discontinued because of
transfer to other facilities for reasons that included
decreased activities of daily life, progressed dementia, or
for nonmedical reasons. There were 13 patients (6 in the
treatment group and 7 in the control group) who dis-
continued because of a new malignancy and 1 patientatients
y Control
(n ¼ 152) p Value Test
67.7  11.2 NS Student t test
<0.05 Fisher’s exact test
62 (40.8)
90 (59.2)
127.7  94.2 <0.01 Student t test
NS Chi-square test
47 (30.9)
7 (4.6)
66 (43.4)
11 (7.2)
21 (13.8)
Student t test
148.8  22.8 NS
76.2  11.8 NS
Fisher’s exact test
20 (13.2) NS
13 (8.6) NS
4 (2.6) NS
Fisher’s exact test
15 (9.9)
57 (37.5)
62 (40.8) NS
13 (8.6) NS
21 (13.8) NS
51.0  5.3 <0.01 Student t test
68.6  5.5 NS Student t test
10.4  2.0 NS Student t test
3.76  0.29 <0.05 Student t test
11.4  7.8 NS Student t test
eptor blocker; ESRD ¼ end-stage renal disease; PCI ¼ percutaneous
Figure 1 Enrollment, Randomization, and Follow-Up of Study Patients
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532who discontinued because of renal transplantation. An
additional 27 patients discontinued spironolactone therapy
because of adverse events (n ¼ 23) or because of with-
drawn consent for nonmedical reasons (n ¼ 4). Figure 1
shows the random assignment and the follow-up of the
patients.
Primary outcome: death fromCCV causes or hospitalization
forCCV causes. During the study, a total of 9 patients (5.7%)
in the treatment group and 19 patients (12.5%) in the controlFigure 2 Cumulative Kaplan-Meier Outcomes Estimates
The Kaplan-Meier curve depicts the rates of primary (A) and secondary (B) outcomes ingroup reached the primary outcome. Kaplan-Meier curves
(Fig. 2A) showed that the patients in the treatment group had
fewer CCV events compared with the control group during
follow-up. The unadjusted HR for spironolactone treatment
was 0.404 (95% CI: 0.202 to 0.809; p ¼ 0.017) and the HR
adjusted by sex, duration of dialysis, and CTR was 0.379 (95%
CI: 0.173 to 0.832; p ¼ 0.016) (Fig. 3). Unadjusted analyses
separating cardiovascular and cerebrovascular causes showed
similar reductions in the risk of each outcome among patientsthe control and treatment groups. HR ¼ hazard ratio.
Figure 3 HRs for Primary and Secondary Outcomes
(A) Unadjusted hazard ratios (HRs) on univariate analyses. Horizontal lines represent 95% conﬁdence intervals (CIs). HRs for some components of primary or secondary
outcomes were not determined because the numbers were not large enough to allow for appropriate analysis. (B) Adjusted HRs on multivariate analyses using Cox proportional
hazards regression models. The HRs indicate the effect of treatment initiation (no treatment to treatment), sex (male to female), 1-month increase in dialysis duration, and 1%
increase in cardiothoracic ratio. CCV ¼ cardiovascular and cerebrovascular; TIA ¼ transient ischemic attack.
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533in the treatment group compared with those in the control
group (HRs of 0.428 and 0.379, respectively), although the
ﬁndings were not signiﬁcant (Fig. 3A).
The HRs for 8 pre-deﬁned subgroups (age, sex, duration
of dialysis, systolic and diastolic blood pressure, the use of
ACEIs or ARBs, CTR, and serum albumin concentration)
were calculated. The reduction in the risk of the primary
outcome in the treatment group was consistent among
subgroups, and none were signiﬁcant in the interaction
tests.
Secondary outcome: death from all causes. There were 10
deaths (6.4%) in the treatment group and 30 (19.7%) in the
control group. Kaplan-Meier curves (Fig. 2B) showed that
the patients in the treatment group had lower all-cause
mortality compared with the control group during follow-
up. The unadjusted HR for spironolactone treatment was
0.355 (95% CI: 0.191 to 0.662; p ¼ 0.002) and the HRadjusted by sex, duration of dialysis, and CTR was 0.335
(95% CI: 0.162 to 0.693; p ¼ 0.003) (Fig. 3). Unadjusted
analyses for death from CCV events, cardiovascular death,
and cerebrovascular death showed similar reductions in the
risk of each outcome among patients in the treatment group
compared with those in the control group (HRs: 0.430,
0.572, and 0.256, respectively), although the ﬁndings were
not signiﬁcant (Fig. 3A).
The HRs for the 8 pre-deﬁned subgroups were calculated
in the same manner as that for the primary outcome. The
reduction in the risk of the secondary outcome in the
treatment group was consistent among subgroups, and none
were signiﬁcant in the interaction tests.
Safety. Blood pressure immediately before dialysis was
measured at each dialysis session. Spironolactone treatment
did not signiﬁcantly affect blood pressure. The blood pres-
sure values in the 98 patients who survived without CCV
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534events under spironolactone treatment were 152.8  22.7/
77.8  14.5 mm Hg at baseline and 152.7  22.0/77.9 
10.9 mm Hg at 3 years. In those patients, the average
potassium concentration did not increase 3 years after
administration of 25 mg/day spironolactone (5.16 mEq/l
at baseline vs. 5.14 mEq/l after 3 years). The adverse reac-
tions in the treatment group are shown in Figure 1. During
the study, only 3 patients discontinued spironolactone
treatment because of hyperkalemia (potassium concentra-
tion: 7.3, 6.7, and 6.6 mEq/l; period from treatment initi-
ation: 35, 0.5, and 1 month, respectively). Gynecomastia or
breast pain was reported by 10% of patients in the treatment
group.Discussion
DOHAS is a randomized, prospective clinical trial com-
paring the efﬁcacy of the addition of spironolactone to the
recommended treatment in patients with ESRD on HD.
The primary outcome, which was a composite of death or
hospitalization because of CCV events, was 5.7% in the
treatment group and 12.5% in the control group. There was
also a signiﬁcant >60% reduction in all-cause mortality
(secondary outcome) in the treatment group. These reduc-
tions, however, cannot be attributed to only the use of spi-
ronolactone because there were some differences (including
duration of dialysis) in baseline characteristics between the 2
groups. However, a Cox model analysis after adjustment for
3 variables (sex, duration of dialysis, and cardiothoracic ratio)
demonstrated signiﬁcant reductions in primary and
secondary outcomes, with corresponding HRs being lower
than unadjusted HRs (Fig. 3). Furthermore, the impact of
dialysis duration on each outcome appeared to be low, since
the HRs for the primary and secondary outcomes were 0.998
and 0.998, respectively (Fig. 3B). Hence, these results
suggest that spironolactone can reduce the number of CCV
events and deaths in HD patients.
The reason for the high risk of CCV disease in HD
patients is not entirely understood (18). The risk factor
proﬁle in these HD patients is markedly different from that
of the general population; this is because these patients have
ill-deﬁned pathophysiologic processes, such as persistent
inﬂammation, endothelial dysfunction, oxidative stress,
autonomic dysfunction, and vascular calciﬁcation, that are
associated with the development of uremic cardiomyopathy
or uremic vascular disease (18,19). Multiple therapeutic
strategies, such as ACEI treatment (6), homocysteine-
lowering therapy (20), intensiﬁed nutrition (21), and
increased dialysis dose (22), have been thought to reduce this
risk, but no survival beneﬁt has been observed with these
strategies. Since the seminal data from RALES, the role of
aldosterone blockade in the reduction of cardiovascular event
risk associated with ESRD has become a topic of interest.
Although the concept of DOHAS is challenging because
spironolactone is currently contraindicated in dialysispatients, this study is unique because it is the “HD patient
version” of RALES and provides evidence for improved
outcomes in HD patients. A novel perspective on aldoste-
rone identiﬁes its pathophysiological role, including the
stimulation of cytokine production and inﬂammatory cell
recruitment (23), augmentation in the production of trans-
forming growth factor and plasminogen activator inhibitor-1
(24), and key regulation of body ion homeostasis (25).
Mineralocorticoid receptors (MRs) exist in not only the
epithelium but also in several nonepithelial sites (including
the brain, heart, and vasculature), and cardiovascular tissues
can also synthesize aldosterone (26). Hence, aldosterone
exerts both paracrine and autocrine effects, and consequently
induces endothelial dysfunction (27), reduces vascular
compliance (28), and causes myocardial and vascular ﬁbrosis
(29). This wide range of aldosterone–MR interactions may
be implicated in the pathophysiology of CCV disease in HD
patients.
An exciting report using spironolactone in HD patients
has recently been published. Administration of 50 mg spi-
ronolactone 3 times per week for 2 years resulted in
a signiﬁcant decrease or even reversal of carotid intima-
medial thickness (30). Carotid intima-medial thickness is
a well-documented marker for CCV risk (31,32) and
correlates with the presence of myocardial infarction and
stroke by cross-sectional analysis (33). Interestingly, the
protective effect of spironolactone on the progression of
carotid intima-medial thickness was observed in the absence
of ACEIs or ARBs (30). In the current study, the use of
ACEIs or ARBs did not affect the superiority of spi-
ronolactone in the occurrence of CCV events. These data
strongly suggest that low-dose spironolactone, even when
used alone, reduces the progression of atherosclerosis and/or
medial enlargement, possibly resulting in the prevention of
CCV events in HD patients.
Aldosterone blockade may play a prominent role in the
prevention of cardiac arrest or arrhythmia in HD patients.
According to the United States Renal Data System database,
62% of all cardiac deaths among HD patients are attribut-
able to cardiac arrest/cause unknown or arrhythmia (34).
One of the mechanisms for this is activation of MRs, which
may directly affect the electrical properties of the ventricle.
Expression of MRs in the myocardium is enhanced in
congestive heart failure (35) and myocardial infarction (36).
Furthermore, under conditions of increased reactive oxygen
species, such as during heart failure and uremia, the
conversion of cortisol to cortisone is inhibited and aldoste-
rone can activate MRs together with cortisol in these
tissues (37). At the cellular level, aldosterone has been
shown to alter the expression of several different ion chan-
nels. These changes may be important contributors to
arrhythmogenesis by the modiﬁcation of cardiac action
potential (38). Activation of MRs also affects ionic current
levels, such as calcium and potassium (25). Taken together,
aldosterone blockade may inhibit ion channel remodeling
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535associated with overstimulation of MRs in cardiomyocytes,
resulting in reduced malignant ventricular arrhythmias in
HD patients, who easily react electrophysiologically to HD
procedures (39).
A previous paper also noted the safety of spironolactone
in HD patients, with spironolactone treatment (50 mg, 3
times per week) showing a tendency to increase serum
potassium concentration by only 0.012 mEq/l per month
during treatment in patients whose serum potassium levels
were <6.0 mEq/l before the administration of spi-
ronolactone, and none of the 33 patients treated with spi-
ronolactone experienced hyperkalemic events during the
24-month follow-up (30). On the other hand, in our pilot
study, the median potassium concentration increased by
0.22 mEq/l in 2 weeks and did not show a subsequent
concentration increase in 50 HD patients who were
administered a spironolactone dose of 25 mg/day (13). In
the current study, 98 patients who survived without CCV
events for 3 years under spironolactone treatment did not
show an increase in average potassium levels, but 3 of
157 patients in the treatment group discontinued spi-
ronolactone treatment because of hyperkalemia. It is an
important consideration that our inclusion criteria for
potassium concentrations may not have been strict enough.
Our study excluded patients with an average serum potas-
sium level of 6.5 mEq/l in the 2 months before treatment,
while other studies excluded those with a serum potassium
level of >6.0 mEq/l (14,30). It should be emphasized that
there was a difference in the time of blood sampling
between these studies. Samples in our study were collected
on the ﬁrst day of the week and those in the other studies
were collected on the second day of the week (14,30).
Because the average increase in the serum potassium levels
immediately before dialysis from the ﬁrst day to the second
day of the week was 0.4 mEq/l in our hospital (Y. Mat-
sumoto, unpublished data, November 2008), our criterion
of <6.5 mEq/l may be comparable to the <6.0 mEq/l level
used in other studies. Regardless of the consideration of
appropriate inclusion criteria, the use of spironolactone in
HD patients appear to be safer than in patients with chronic
kidney disease not undergoing dialysis.
Study limitations. First, this study was not blinded.
Further, a placebo was not administered to the control
group. Additionally, the interaction tests were underpow-
ered, and the number of endpoints was small. Therefore,
further large-scale prospective, randomized, blinded trials
with adequate power are required to conﬁrm these results.Conclusions
This study showed that low-dose spironolactone can be
safely administered for a long duration to HD patients, and
it may reduce CCV events and all-cause mortality. We
believe that spironolactone may be a useful therapy for
improving the currently poor prognosis of HD patients;however, larger-scale studies are necessary to conﬁrm our
results.
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